Hyung S. Park - Publications

Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight.

Journal: International journal of obesity (2005)

Published: March 13, 2026

Molecular and clinical disparity of EGFR-mutant non-small cell lung cancer (NSCLC) based on histopathological stage and EGFR molecular subtypes.

Journal: Translational lung cancer research

Published: November 26, 2025

Erratum to "Autophagy inhibition enhances sensitivity of alpelisib in PI3K-mutated non-small cell lung cancer" [Biomed. Pharmacother. 192 (2025), 118620].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: October 17, 2025

Targeting PON2 with Vutiglabridin Restores Mitochondrial Integrity and Attenuates Oxidative Stress-Induced Senescence.

Journal: Antioxidants (Basel, Switzerland)

Published: September 24, 2025

Paraoxonase 2 as a target for aging-related diseases.

Journal: The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology

Published: September 16, 2025

Vutiglabridin ameliorates obesity by directly reducing fat mass through AMPK/lipophagy activation in adipocytes.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: August 31, 2025

Autophagy inhibition enhances sensitivity of alpelisib in PI3K-mutated non-small cell lung cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 17, 2025

Liposomal irinotecan with fluorouracil and leucovorin as salvage treatment for advanced biliary tract cancer refractory to gemcitabine and cisplatin.

Journal: Frontiers in oncology

Published: June 18, 2025

Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson's disease.

Journal: Molecular neurodegeneration

Published: October 20, 2024

Real-world outcomes of fluorouracil-based second-line therapy in patients with advanced biliary tract cancer refractory to gemcitabine and cisplatin-based treatment.

Journal: Therapeutic advances in medical oncology

Published: October 19, 2024

Common Cancer-Related Factors and the Risk of Developing Kaposi Sarcoma in Individuals without AIDS: Korea National Health Insurance Services Claims Database.

Journal: Journal of clinical medicine

Published: August 13, 2024

New insights into ATR inhibition in muscle invasive bladder cancer: The role of apolipoprotein B mRNA editing catalytic subunit 3B.

Journal: Oncology research

Published: December 21, 2023